Specifically, in RA, SRC promotes invasive migration of synovial fibroblasts through the RhoA/ROCK pathway (74); In CKD, SRC reduces renal tubulointerstitial inflammatory infiltration by negatively regulating the NF-κB/MAPK signaling axis and inhibits collagen deposition via the TGF-βR/EGFR signaling axis (54, 55, 69); while EGFR drives VEGF-mediated pannus formation in RA (75) yet activates TGF-β1/Smad3 phosphorylation to induce EMT in CKD (76). Here, EGFR is linked to chronic kidney disease.